fig4
![Long-term efficacy and safety of cardiac genome editing for catecholaminergic polymorphic ventricular tachycardia](https://image.oaes.cc/ee1aec41-cfe5-4249-885e-6af5c275a2c8/jca4042.fig.4.jpg)
Figure 4. Unaltered cardiac function following long-term genome editing. (A) Representative short-axis M-mode echocardiography images of the left ventricle of R176Q/+ mice treated with control (Con) AAV9 or gRNA-SaCas9, or WT littermate mice, at 4, 8, and